R. Mera et al., Eradication of Helicobacter pylori infection with proton pump-based tripletherapy in patients in whom bismuth-based triple therapy failed, J CLIN GAST, 29(1), 1999, pp. 51-55
To study the effects of treatment of Helicobacter pylori infection in a hyp
erendemic population, 143 infected patients from the region of Narino, Colo
mbia, were heated for 2 weeks with clarithromycin (500 mg twice a day), amo
xicillin (1 g twice a day), and either lansoprazole (30 mg twice a day) or
omeprazole (30 mg twice a day). All patients belong to a low socioeconomic
strata, had multifocal atrophic gastritis documented by gastric biopsies, a
nd had been treated previously and unsuccessfully for 2 weeks with bismuth
subsalicylate (262 mg four times a day), amoxicillin (500 mg three times a
day), and metronidazole (400 mg three times a day). C-13-urea breath tests
were performed 6, 12, 24, and 60 weeks after completing therapy. The C-13-u
rea breath test was negative in 79.7% of patients 1 month after finishing t
herapy, and in 69.2% of patients 1 year after finishing treatment. There we
re no differences in eradication rates between patients treated with omepra
zole versus lansoprazole. Dyspepsia symptoms decreased from 74% in patients
at baseline to 19% at the time of finishing treatment. In low-socioeconomi
c status populations with hyperendemic infection, triple therapy using omep
razole or lansoprazole plus clarithromycin and amoxicillin is an effective
alternative when previous standard bismuth-based triple therapy has failed.